GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (STU:1S90) » Definitions » Short Percentage of Float

Seres Therapeutics (STU:1S90) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Seres Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Seres Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seres Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's Short Percentage of Float falls into.


;
;

Seres Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (STU:1S90) » Definitions » Short Percentage of Float
Comparable Companies
IFRX XBIT ANIX NAUT PLRX EXOZ VOR CLYM BDTX VTYX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
MCRB:USA 1S9:Germany
Address
101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Website
https://www.serestherapeutics.com
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Headlines

No Headlines